Centre Regional Lutte Contre Le Cancer — Clinical Trial Site

53 Registered trials

26 Currently recruiting

Organisation

Centre Regional Lutte Contre Le Cancer

Location

Strasbourg, France

Identifier

ORG-100054755

Address

Batiment Icans, 17 Rue Albert Calmette, 67200, France

Departments

#1004: Medical Oncology
#2101: Nuclear Medecine
#2155A; Oncologie
4005: Oncologie medicale
Gastro - entérologie
Gastroenterology
Médecine nucléaire
Medical oncolgy
Medical Oncology
N/A
Nuclear medicine
oncologie
Oncologie médicale
Oncology
radiotherapie
Radiotherapy
Service de pathologie mammaire
Service de radiothérapie
Service oncologie medicale

Clinical trials at this site (53)

Search interface

Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric… Recruiting

2023-504618-31-00 Chemotherapy induced peripheral neuropathy (CIPN) 5 2023-10-20
Evaluation of diagnostic performances of 18F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliom… Recruiting

2022-501688-42-00 Low Grade Glioma 5 2023-05-24
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib … Recruiting

2022-503068-34-00 Metastatic Gastrointestinal Stromal Tumor 4 2022-04-06
RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR … Recruiting

2022-502642-27-00 RElapse in previously irradiated Prostate bed 9 2020-11-26
Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine ad… Recruiting

2024-514603-34-00 intermediate-risk differentiated thyroid cancer patient 5 2020-03-02
PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended

2025-521302-17-00 Hihg risk of cholangiocarcinoma intra hépatic resectabl 10 2026-05-26
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma Ended

2024-517114-15-00 newly diagnosed gliblastoma 7 2025-03-07
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Breast Cancer 9 2024-10-02
A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended

2023-506054-20-00 Adenocarcinoma of the biliary tract (intrahepatic or ex 5 2024-06-05
Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended

2022-502916-35-01 Advanced Non-Small Cell Lung Cancer 4 2024-03-27
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants… Ended

2022-502465-18-00 Advanced or metastatic breast cancer 9 2024-02-15
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended

2022-503040-41-00 PSMA PET scan positive Castration-Resistant Prostate Ca 4 2024-02-09
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended

2022-501493-19-00 metastatic Castration-Resistant Prostate Cancer (mCRPC) 5 2023-02-20
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended

2023-507970-42-00 PSMA-positive metastatic hormone-sensitive prostate can 5 2021-03-31
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23